Free Trial
TSE:GEN

GeneNews (GEN) Stock Price, News & Analysis

GeneNews logo

About GeneNews Stock (TSE:GEN)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
473,147 shs
Average Volume
1.48 million shs
Market Capitalization
C$25.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

GeneNews Limited focuses on developing and commercializing proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. GeneNews Limited was founded in 1998 and is headquartered in Richmond Hill, Canada.

Remove Ads
Receive GEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GeneNews and its competitors with MarketBeat's FREE daily newsletter.

GEN Stock News Headlines

GeneNews: Q1 Earnings Snapshot
Trump… a socialist?
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Headlines

GEN Stock Analysis - Frequently Asked Questions

Shares of GEN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that GeneNews investors own include MARA (MARA), Ocugen (OCGN), Spero Therapeutics (SPRO), American Airlines Group (AAL), First Majestic Silver (AG) and Antibe Therapeutics (ATE).

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
Computer Software
Current Symbol
TSE:GEN
CIK
N/A
Fax
N/A
Employees
2,700
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$234,592.00
Price / Cash Flow
145.00
Book Value
C($0.06) per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
C$25.49 million
Optionable
Not Optionable
Beta
N/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (TSE:GEN) was last updated on 4/1/2025 by MarketBeat.com Staff
From Our Partners